BioCardia (BCDA) Accounts Payables (2010 - 2026)
BioCardia's (BCDA) quarterly Accounts Payables came in at $541000.0 in Q2 2026, down 56.12% year-over-year from $1.2 million in Q2 2025, and down 34.02% quarter-over-quarter from $820000.0 in Q1 2026.
Powered by 
Analysis
BioCardia (BCDA) Accounts Payables (2010 - 2026) Analysis & Trends
BioCardia (BCDA) has reported Accounts Payables for 16 consecutive years, with $541000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Accounts Payables fell 56.12% year-over-year to $541000.0 in Q2 2026; TTM through Jun 2026 was $541000.0, a 56.12% decrease from a year earlier, with the FY2025 full-year figure at $641000.0, up 66.49% from the prior year.
- Accounts Payables was $541000.0 for Q2 2026 at BioCardia, down from $820000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.4 million in Q2 2024 and troughed at $385000.0 in Q4 2024.
- A 5-year average of $824500.0 and a median of $819000.0 in 2025 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 110.93% in 2024, down 56.74% in 2024.
- Over 5 years, Accounts Payables stood at $683000.0 in 2022, then soared by 30.31% to $890000.0 in 2023, then tumbled by 56.74% to $385000.0 in 2024, then jumped by 66.49% to $641000.0 in 2025, then fell by 15.6% to $541000.0 in 2026.
- The last three Accounts Payables figures came in at $541000.0 (Q2 2026), $820000.0 (Q1 2026), and $641000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 6.54 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | 11.31 Mn |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 26.21 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 77.30 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 4.98 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | 13.10 Mn |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 5.30 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 50.98 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 20.61 Mn |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | 541,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 541,000.00 |
| Mar 31, 2026 | 820,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Mar 31, 2025 | 818,000.00 |
| Dec 31, 2024 | 385,000.00 |
| Sep 30, 2024 | 569,000.00 |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 890,000.00 |
| Sep 30, 2023 | 507,000.00 |
| Jun 30, 2023 | 686,000.00 |
| Mar 31, 2023 | 861,000.00 |
| Dec 31, 2022 | 683,000.00 |
| Sep 30, 2022 | 887,000.00 |
| Jun 30, 2022 | 999,000.00 |
| Mar 31, 2022 | 764,000.00 |
| Dec 31, 2021 | 507,000.00 |
| Sep 30, 2021 | 846,000.00 |